News | November 12, 2021
Covaxin well tolerated with no safety concerns: Lancet
Covaxin is the only Covid-19 vaccine to have demonstrated efficacy data from phase III clinical trials against the Delta variant at 65.2%
Covaxin is the only Covid-19 vaccine to have demonstrated efficacy data from phase III clinical trials against the Delta variant at 65.2%
It was recognized for its holistic initiatives designed to improve the quality of life and standards of care for patients
Trivector Biomed has been promoting its Novaerus air disinfection solution across hospitals and health care facilities across India.
This capability programme aims to upskill 5000 nurses across the country in the next year by converting the current modules into an e-learning one
India reports 18 lakh stroke cases a year with 25 per cent patients below the age of 50
It has exercised intellectual property options from IP Group regarding research results generated by the UK Cystic Fibrosis Gene Therapy Consortium, and from Oxford Biomedica regarding their lentiviral vector technology
The panel concurred that these supplements resolved post-Covid-19 fatigue and muscle weakness
_256_384.jpg)
It works by collecting aerosols and identifies the presence of dangerous pathogens using sensitive, specific and rapid detection in near-real time without laboratory analysis
_256_384.jpg)
The two doses of Covaxin are likely to be administered to children with a gap of 28 days
The start-up claims in clinical trials over 90 % achieved type 2 diabetes reversal and 92 % eliminated all diabetes medication within 90 days of joining the twin service
Subscribe To Our Newsletter & Stay Updated
